News > Covaxin shows 50% effectiveness against symptomatic COVID-19: Study

Covaxin shows 50% effectiveness against symptomatic COVID-19: Study

Two doses of Covaxin are 50 percent effective against the symptomatic disease, according to the first real-world assessment of India's indigenous COVID-19 vaccine published in The Lancet Infectious Diseases journal.

Results of an interim study recently published in The Lancet showed that two doses of Covaxin, also known as BBV152, had 77.8 percent efficacy against symptomatic disease and present no serious safety concerns.